• ARCA Biopharma Inc., of Broomfield, Co., filed for a public offering of $20 million in stock and warrants to fund the Phase IIb portion of the GENETIC-AF trial of Gencaro (bucindolol hydrochloride) for atrial fibrillation. Dawson James Securities Inc. is the lead placement agent.
